跳至主要内容
临床试验/NCT06383689
NCT06383689招募中不适用

Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring (OPERA)

University Hospital, Bonn1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年5月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
90
试验地点
1
主要终点
Latency to first epileptic seizure

研究概览

简要总结

The notion of genuine placebo effects on epileptic seizure events (i.e., effects beyond methodological study artifacts) is incompatible with the standard model of epilepsy seizure genesis. In this single-blind controlled study, the effectiveness of a covered placebo on (1) the timing of the occurrence of a first epileptic seizure ("seizure pill") versus (2) the subjective well-being ("comfort pill") during pre-surgical video-EEG monitoring will be examined. It is hypothesized that a placebo effect on subjective well-being can be demonstrated, but that epileptic seizure events are not influenced by placebo.

详细描述

Patients undergoing long-term video-EEG monitoring for the purpose of pre-operative epilepsy diagnostics will be invited to participate in the study. Patients will be pseudo-randomized into three study conditions (in blocks of six). The study participants will take a placebo pill designated either as a "seizure pill" (Condition PCB-S) or a "comfort pill" (PCB-W) in addition to their regular medication in the morning and evening, or not receive any additional placebo medication (No-PCB).

Both the "seizure pill" and the "comfort pill" are commercially available, ingredient-free placebo pills (P-pills blue Lichtenstein, produced by Winthrop Pharmaceuticals). No further details about the composition of the pill will be provided; information about the ingredients of the respective pill will be provided after the end of the entire study. Depending on randomization, study participants will be informed that this pill is expected to (1) either facilitate/accelerate the occurrence of epileptic seizures (PCB-S) (thereby shortening the required time for video-EEG monitoring), or (2) to lead to a more stable/improved emotional well-being during the stay in the V-EEG (PCB-W) or (3) will not receive a pill but are asked to fill-in questionnaires and diaries like the other patients.Start of the V-EEG will be documented as the starting point for latency measurement for the occurrence of a first epileptic seizure. The patients will be pseudo-randomized into the three study conditions: Out of every 6 patients, 2 will be assigned to each of the three study conditions. Patients in both active study conditions will receive the first pill at the start of the V-EEG. After that, study participants will receive the respective "pill" morning and evening in addition to their other medications, however, visibly separated from them and clearly marked as study medication. All participants, including controls, will keep a seizure diary during the V-EEG. In addition, they will fill-in a newly constructed ad-hoc questionnaire at the beginning and after the V-EEG. Finally, all patients will be asked twice daily (around 9 AM and around 6 PM) about their overall emotional well-being using a visual analogue scale (VAS; 0 very bad ... 100 extremely good). The highly standardized clinical procedures of presurgical evaluation are in no way affected by the study. In particular, anti-seizure medications for all patients will be tapered off following exactly the same schedule without any influence from the study; the medication will be precisely documented.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Participant)

盲法说明

Like in psychological studies, only patients can participate in the study who consent to accept that complete study information can only be provided after the entire study was finished (with an option to withdraw consent at that point) as information on ingredients of the study pill (which is placebo) must be concealed for inherent reasons (study on effects of covered placebo).

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •eligibility for presurgical epilepsy diagnostics

排除标准

  • •inclusion criterion implies all exclusion criteria for this procedure
  • •legal guardian
  • •lack of consent or lack of capability to provide informed consent

研究组 & 干预措施

Seizure placebo pill (PCB-S)

Experimental

Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible acceleration of the occurrence of an epileptic seizure (which then allows to conclude V-EEG monitoring faster)

干预措施: Seizure placebo pill (Other)

Well-being placebo pill (PCB-W)

Experimental

Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible improvement of emotional well-being during the demanding V-EEG monitoring procedure

干预措施: Well-being placebo pill (Other)

No pill (control)

No Intervention

Patients assigned to this condition receive no study pill but are asked to fill-in all questionnaires and diaries like patients in the two active arms

结局指标

主要结局

Latency to first epileptic seizure

时间窗: immediately after video-EEG monitoring

temporal latency from beginning of the video-EEG monitoring to the occurrence of the first epileptic seizure

次要结局

  • Emotional well-being(immediately after video-EEG monitoring)
  • Number of early occurring epileptic seizures(72 hours after video-EEG monitoring)
  • Daily average frequency of epileptic seizures(immediately after video-EEG monitoring)
  • Very early first epileptic seizure(after 1st day after video-EEG monitoring)
  • Epileptic seizure within the first three days(after 3rd day after video-EEG monitoring)
  • Early occurrence of an epileptic seizure within the first 72 hours(immediately after video-EEG monitoring)
  • Number of epileptic seizures during the video-EEG(immediately after video-EEG monitoring)
  • Early epileptic seizure(after 2nd day after video-EEG monitoring)
  • Dissociative non-epileptic seizures(immediately after video-EEG monitoring)
  • Occurrence of an epileptic seizure(immediately after video-EEG monitoring)

研究者

发起方
University Hospital, Bonn
申办方类型
Other
责任方
Principal Investigator
主要研究者

Christian Hoppe

Senior Researcher (Clinical Neuropsychologist)

University Hospital, Bonn

研究点 (1)

Loading locations...

相似试验